Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine vs ropivacaine PENG + lateral femoral cutaneous nerve block in hip arthroplasty
ChiCTR2600121298Phase 4Not yet recruiting
- Sponsor
- Wuhan Central Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by Wuhan Central Hospital. Primary endpoint: Dynamic NRS pain score at 48 hours postoperatively. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600121298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121298.